Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.

You may also be interested in...



Deals Of The Week: Tire-Kicking Season Continues Full-Swing

As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.

Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups

Second-generation therapeutics are moving into the clinic following Celgene’s successful gamble on Abraxane. New nanobiotechs proliferate, but an industry burned by other promising technology revolutions remains somewhat wary of investing in early-stage firms.

Deerfield Management Opts For More Private Investment And A New Public Face

Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel